Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 9481 Neoplasms 6589 Prostatic Neoplasms 4399 Colorectal Neoplasms 3978 Lung Neoplasms 3644 Carcinoma, Non-Small-Cell Lung 3585 Pancreatic Neoplasms 2479 Carcinoma, Hepatocellular 2413 Leukemia, Myeloid, Acute 2265 Multiple Myeloma 2121 Stomach Neoplasms 2109 Neoplasm Metastasis 1911 Head and Neck Neoplasms 1870 Ovarian Neoplasms 1773 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1734 Lymphoma 1730 Brain Neoplasms 1702 Rectal Neoplasms 1676 Melanoma 1656 Colonic Neoplasms 1629 Leukemia 1500 Uterine Cervical Neoplasms 1499 Recurrence 1486 Esophageal Neoplasms 1312 Glioblastoma 1308 Lymphoma, Non-Hodgkin 1205 Leukemia, Lymphocytic, Chronic, B-Cell 1120 Squamous Cell Carcinoma of Head and Neck 1109 Urinary Bladder Neoplasms 1078 Lymphoma, Follicular 1067

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡